Neglected tropical diseases (NTDs) are a collection of infectious diseases that contribute to a significant level of morbidity and mortality, particularly in the developing world. For example, human African trypanosomiasis (HAT) is caused by the insect-borne protozoan pathogen *Trypanosoma brucei*, and the resulting infection results in 1.6 million disability-adjusted life years.^[@ref1]^ Although the disease burden caused by these NTDs is high, there is little financial incentive to engage in the costly process for the discovery and development of drugs, which leaves a current pharmacopeia of mixed efficacy, safety, and convenience. To wit, one of the front-line treatments for HAT is melarsoprol, which is a brain-penetrant organoarsenic agent that itself has at least a 5% mortality rate.^[@ref2]^

As a result, we and others have been advancing efforts to repurpose classes of investigational drug agents as new leads for HAT and other NTDs. Termed "target repurposing"^[@ref3]^ or "piggy-back"^[@ref4]^ drug discovery, these efforts entail assessment of established inhibitors of human enzymes that are homologous to essential parasite enzymes and pursuit of these and related analogues as a launching point for new antiparasitic agents. We have found that kinase inhibitors represent a particularly fertile area for application of target repurposing,^[@ref5]−[@ref9]^ and our pursuit of this family of inhibitors led to a high-throughput kinase-targeted inhibitor screen against *T. brucei*. In that 42444 compound screening campaign we identified 797 potent (pEC~50~ ≥ 6) and selective (\>100×) inhibitors of the bloodstream form of the parasite.^[@ref10]^

Included in the high-throughput screening (HTS) set was the Published Kinase Inhibitor Set (PKIS) released by GlaxoSmithKline (GSK), which consists of a set of 369 kinase inhibitor compounds with inhibitory data available against 224 human kinases at two concentrations (0.1 and 1 μM), providing information regarding each compound's human kinase selectivity.^[@ref11]^ Publicly available in screening plates upon request from GSK, this inhibitor set has been utilized by a number of research groups outside GSK, culminating in a number of papers describing exploration of a wide range of programs of relevance to human health.^[@ref12]^

During the analysis of our HTS results, we noted that there were particular families of kinase inhibitors present in the PKIS collection that showed high potency against *T. brucei*, with good-to-excellent selectivity over host cells (HepG2, see Table S1 in the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.5b00136/suppl_file/id5b00136_si_001.pdf)). This observation led us to ask whether a more rigorous analysis of the PKIS screening hits might uncover more information about which human kinases may share inhibitor sensitivity similar to that of *T. brucei* cells in vitro.

Although target repurposing approaches are most often launched by a bioinformatic analysis that matches human-to-parasite based on *target protein sequence similarity*, we hypothesized that an analysis of the PKIS may lead to an ability to match on the basis of similarity of *inhibitor sensitivity*. Such an analysis could allow a more focused approach to repurposing established kinase inhibitor chemotypes, even in the absence of information about specific parasite target inhibition. We felt that this approach could be valuable given previous work that demonstrated that repurposing chemical matter from human homologues can be successful and be causing their effect, at least in part, by inhibition of the parasite homologue, such as for Aurora kinase,^[@ref13]^ or GSK3β.^[@ref14]^ However, because much is unknown about the function of many *T. brucei* kinases, multiple targets may be contributing to the antiproliferative effects of a given kinase inhibitor, as was observed for DDD34425, a potent inhibitor of *T. brucei* PK50.^[@ref14]^ Furthermore, although *T. brucei* does not express canonical protein tyrosine kinases,^[@ref15]^ human tyrosine kinase inhibitors have previously been successfully repurposed to launch lead discovery programs.^[@ref7],[@ref16]^

In light of these observations, we wished to utilize the unique juxtaposition of *T. brucei* and human kinase activity data to identify whether there was a significant probability that inhibitors of particular human kinases were more active against *T. brucei* when compared to a wider set of kinase inhibitors and whether these might provide a good starting point to launch new lead discovery efforts, even in the absence of parasite target information.

To accomplish this, we systematically analyzed the PKIS data to find statistical associations between human kinase inhibition and *T. brucei* inhibition. Before that, the 369 compounds included in the PKIS were assessed for completeness of data: despite meeting the primary HTS cutoff, four compounds had incomplete EC~50~ data against *T. brucei* cells, and/or HepG2 cellular selectivity data. Thus, the overall compound set was reduced to 365.

Compounds were binned on the basis of their *T. brucei* pEC~50~ ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). For the human kinase inhibitory analysis, each compound was assigned a score on the basis of whether the compound showed ≥70% inhibition (scored 1) or \<70% inhibition (scored 0) at 0.1 μM. The total number of inhibiting compounds was calculated for each kinase. In general, these calculations gave us the number of compounds with a *T. brucei* pEC~50~ in a particular range (e.g., pEC~50~ ≥ 6) that displayed an inhibitory activity against the selected human kinase higher than or equal to the selected cutoff of 70% inhibition at 0.1 μM. This process was repeated for higher cutoff values of kinase inhibition (≥80 and ≥90% inhibition at 0.1 μM) and for several *T. brucei* pEC~50~ ranges. A total of 2016 2×2 contingency tables were constructed. Fold enrichments were calculated, and a chi-squared contingency table test was performed to evaluate the statistical significance of the enrichments.^[@ref17],[@ref18]^ A contingency table was considered significant when its chi-squared test *p* value was \<0.01.

###### Inhibitors Binned on the Basis of *T. brucei* Proliferation Inhibition

  pEC~50~ range   no. of compounds
  --------------- ------------------
  \<4             253
  ≥4              112
  ≥6              53
  ≥7              13

The contingency tables for each kinase were then sorted by their fold enrichment (see [Methods](#sec2){ref-type="other"} for definition). In the interest of using the same cutoff value as used in the original *T. brucei* HTS, we elected to utilize the pEC~50~ ≥ 6 cutoff to denote "active" parasite proliferation inhibitors, which provided a large enough sample to provide a statistically valid analysis. The highest-scored kinases (by fold enrichment) and their respective *p* values are reported in [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}.

###### Highly Scored Human Kinases for Active *T. brucei* Inhibitors Defined as pEC~50~ ≥ 6, Grouped by Human Kinase Percent Inhibition Cutoffs[a](#tbl2-fn1){ref-type="table-fn"}

                                  70% inhibition cutoff   80% inhibition cutoff   90% inhibition cutoff                            
  -------------- ------- -------- ----------------------- ----------------------- ----------------------- ---------------- ------- ----------------
  DYRK1B         CMGC    6 (6)    41.20                   6.06 × 10^--8^          35.32                   1.19 × 10^--6^            
  DYRK1A         CMGC    6 (6)    41.20                   6.06 × 10^--8^          23.54                   3.92 × 10^--4^            
  ARK5           CAMK    4 (4)    29.43                   2.24 × 10^--5^                                                            
  CDK1/cyclinB   CMGC    3 (3)    23.54                   3.92 × 10^--4^                                                            
  CDK3/cyclinE   CMGC    3 (3)    23.54                   3.92 × 10^--4^                                                            
  HIPK1          CMGC    6 (5)    17.66                   1.07 × 10^--5^          17.66                   1.07 × 10^--5^            
  CDK5/p35       CMGC    2 (2)    17.66                   6.17 × 10^--3^                                                            
  NEK9           other   2 (2)    17.66                   6.17 × 10^--3^                                                            
  HIPK4          CMGC    2 (2)    17.66                   6.17 × 10^--3^                                                            
  LCK            TK      2 (2)    17.66                   6.17 × 10^--3^                                                            
  GSK3α          CMGC    13 (9)   11.77                   4.26 × 10^--8^          11.77                   5.89 × 10^--5^            
  CLK2           CMGC    7 (5)    11.77                   5.89 × 10^--5^          11.77                   5.89 × 10^--5^   17.66   1.07 × 10^--5^
  TSSK1          CAMK    7 (5)    11.77                   5.89 × 10^--5^          11.77                   5.89 × 10^--5^   17.66   6.17 × 10^--3^
  LRRK2          TKL     7 (5)    11.77                   5.89 × 10^--5^          9.81                    7.05 × 10^--4^            
  ROS            TK      7 (5)    11.77                   5.89 × 10^--5^                                                            
  GSK3β          CMGC    12 (8)   10.59                   5.65 × 10^--7^          9.81                    7.05 × 10^--4^            
  LTK            TK      9 (6)    10.30                   2.04 × 10^--5^          7.35                    2.22 × 10^--3^   9.81    7.05 × 10^--4^
  CDK2/cyclinE   CMGC    9 (6)    10.30                   2.04 × 10^--5^          17.66                   6.17 × 10^--3^            
  TTK            other   6 (4)    9.81                    7.05 × 10^--4^                                                            
  IRR            TK      8 (5)    8.83                    2.29 × 10^--4^          7.84                    7.14 × 10^--3^   7.84    7.14 × 10^--3^
  CDK2/cyclinA   CMGC    13 (8)   8.83                    2.23 × 10^--6^          8.24                    7.37 × 10^--5^            
  IGF1R          TK      10 (6)   8.24                    7.37 × 10^--5^          8.24                    7.37 × 10^--5^   10.30   2.04 × 10^--5^
  ALK            TK      10 (6)   8.24                    7.37 × 10^--5^          7.06                    6.95 × 10^--4^            
  LRRK2-G2019S   TKL     5 (3)    7.84                    7.14 × 10^--3^          11.77                   2.13 × 10^--3^            
  PYK2           TK      9 (5)    7.06                    6.95 × 10^--4^                                                            
  INSR           TK      11 (6)   6.86                    2.18 × 10^--4^          6.86                    2.18 × 10^--4^   7.06    6.95 × 10^--4^
  PLK1--002      other   16 (8)   5.88                    5.37 × 10^--5^          8.83                    2.23 × 10^--6^   11.77   1.61 × 10^--6^
  ABL-Q252H      TK      5 (3)                                                    7.84                    7.14 × 10^--3^            
  ABL-M351T      TK      3 (2)                                                    7.84                    7.14 × 10^--3^            

Kinases with missing data do not display a statistically significant enrichment at the respective percent inhibition cutoff.

*N*, number of inhibitors from the PKIS that show ≥70% inhibition of the preferred kinase at 0.1 μM concentration; the number in parentheses represents the number of these inhibitors with *T. brucei* pEC~50~ ≥ 6.

On the basis of these results, we note that the most highly scored kinases belong to the human CMGC kinase family, which includes DYRK, CDK, GSK-3, and HIPK. Lower fold enrichment values have been found for tyrosine kinases (TK) (LCK, ROS, LTK, IGF1R, ALK, PYK2, INSR, and ABL mutant variants) and tyrosine-kinase-like kinases (TKL) (LRRK2 and its mutant variant LRRK2-G2019S). A graphical representation of the kinase enrichment scores, grouped by kinase family, is reported in [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}.

![Fold enrichment of human kinases, grouped by family, using three human kinase percent inhibition cutoffs (70, 80, and 90%). Kinases missing histogram bars do not display a statistically significant enrichment at the respective percent inhibition cutoff.](id-2015-00136b_0002){#fig1}

The translation of these observations to prospective application would be desirable. Thus, on the basis of the statistical analysis performed, we selected from commercial vendors 26 established inhibitors of the "preferred" human kinases (Tables S2 and S3, [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.5b00136/suppl_file/id5b00136_si_001.pdf)). To assess the structural similarity of the commercial inhibitors with the PKIS compounds, the Tanimoto coefficients between all of the former were calculated against all of the latter. We wished to ensure that any enhancement to the hit rate would not be the result of testing close analogues of the original PKIS compounds. The similarity assessment results are shown in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"} in the form of box plots that show the range of structural similarity between the purchased compounds and PKIS inhibitors, grouped by the preferred kinase. (These data are also found in Table S4 of the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.5b00136/suppl_file/id5b00136_si_001.pdf).)

![Box plots showing Tanimoto scores of the purchased kinase inhibitors shown in [Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"} to members of the PKIS that inhibit the same primary human target. The primary human target is defined as the highest percent inhibition at 0.1 μM drug concentration.](id-2015-00136b_0003){#fig2}

###### Inhibitors of Preferred Human Kinase Purchased and Tested against Protozoan Pathogens and Host Cells

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                            *T. brucei*   *Leishmania*   *T. cruzi*   *P. falciparum*   host cell tox                          
  -------- ---------- ---------------- -------------------- ------------- -------------- ------------ ----------------- --------------- ------- ------- ------ --------
  **1**    NEU-838    crizotinib       ALK\                 6.4           6.2            5.8          5.1               6.1             7.4     7.0     4.8    5.4
                                       (7.6)                                                                                                                   

  **2**    NEU-844    TAE684           ALK\                 7.0           6.5            5.9          5.3               6.3             6.4     6.3     4.6    5.3
                                       (8.5)                                                                                                                   

  **3**    NEU-893    GSK1838705A      ALK\                 5.7           \<4.6          \<4.8        5.0               5.6             5.8     5.8     4.8    5.1
                                       (9.3)                                                                                                                   

  **4**    NEU-967    NVP-AEW5414      IGF-1R\              5.7           7.0            5.4          5.4               5.9             6.0     5.9     4.8    5.5
                                       (6.8)                                                                                                                   

  **5**    NEU-968    BMS-2652465      CDK1-cyclinB (8.2)   6.3           6.6            \<4.8        \<4.3             4.8             5.0     4.9     \<4    \<4.4

  **6**    NEU-969    PHA-8481256      CDK2-cyclinA (7.3)   7.6           6.5            5.3          7.4               5.2             5.1     5.2     \<4    5.0

  **7**    NEU-970    GSK1904529A7     IGF-1R\              5.9           \<4.9          5.5          \<4.3             6.8             7.0     6.9     \<4    \<4.4
                                       (7.6)                                                                                                                   

  **8**    NEU-971    JNJ-77066218     CDK2-cyclinE (8.5)   6.5           \<4.6          \<4.8        \<4.3             5.7             6.0     5.9     \<4    5.2

  **9**    NEU-973    ON-019109        PLK1\                \<5.5         \<4.6          \<4.8        \<4.3             \<4.7           \<4.7   \<4.7   \<4    \<4.4
                                       (8.0)                                                                                                                   

  **10**   NEU-974    CH542480210      ALK\                 \<5.5         6.9            \<4.8        \<4.3             5.4             \<4.7   \<4.7   \<4    \<4.4
                                       (8.7)                                                                                                                   

  **11**   NEU-975    dinaciclib       CDK2\                7.4           5.8            5.6          7.0               5.9             6.1     6.5     \<4    \<4.4
                                       (9.0)                                                                                                                   

                                       P35/CDK5 (9.0)                                                                                                           

  **12**   NEU-976    linsitinib       IGF1R\               \<5.5         5.1            \<4.8        5.0               6.3             5.7     6.3     \<4    4.5
                                       (7.5)                                                                                                                   

  **13**   NEU-977    roscovitine 13   P35/CDK5\            \<5.5         5.2            \<4.8        \<4.3             6.1             5.7     5.7     \<4    4.5
                                       (9.0)                                                                                                                   

  **14**   NEU-978    CHIR-9801414     GSK3α/β\             \<5.5         5.2            \<4.8        \<4.3             \<4.7           \<4.7   \<4.7   \<4    4.8
                                       (9.2)                                                                                                                   

  **15**   NEU-979    volasertib       PLK1\                \<5.5         5.8            5.1          4.9               6.8             6.8     6.8     4.6    5.5
                                       (9.1)                                                                                                                   

  **16**   NEU-980    BI 253616        PLK1\                6.2           5.4            5.1          4.7               7.7             8.0     7.9     4.5    5.6
                                       (9.1)                                                                                                                   

  **17**   NEU-982    AT751918         p35/CDK5\            6.5           \<4.6          \<4.8        5.9               5.9             6.1     6.5     \<4    \<4.4
                                       (7.9)                                                                                                                   

  **18**   NEU-984    SNS-03219, 20    CDK9/cyclinT\        6.9           \<4.6          \<4.8        \< 4.3            5.3             5.5     5.7     \<4    \<4.4
                                       (8.4)                                                                                                                   

  **19**   NEU-985    AZD543821        CDK2/cyclinE\        7.5           6.4            5.6          5.8               5.9             6.0     5.9     \<4    4.9
                                       (8.2)                                                                                                                   

  **20**   NEU-986    SB 41528622      GSK-3α\              6.1           \<4.6          \<4.8        \<4.3             4.8             4.6     4.6     4.2    \<4.4
                                       (7.1)                                                                                                                   

  **21**   NEU-987    flavopiridol     CDK1/2/4/6\          6.8           6.4            5.5          4.9               5.7             5.7     5.8     \< 4   \< 4.4
                                       (7.4)                                                                                                                   

  **22**   NEU-989    TWS11925         GSK-3β\              6.0           4.7            \<4.8        \<4.3             5.0             4.7     5.1     4.4    \<4.4
                                       (7.5)                                                                                                                   

  **23**   NEU-990    SB 21676322      GSK-3α\              \<5.5         5.6            \<4.8        \<4.3             \<4.7           \<4.7   \<4.7   \<4    \<4.4
                                       (7.5)                                                                                                                   

  **24**   NEU-991    tideglusib       GSK-3β\              \<5.5         6.5            \<4.8        4.7               4.6             4.6     4.7     4.1    \<4.4
                                       (7.2)                                                                                                                   

  **25**   NEU-1007   PHA-79388727     p25/CDK5\            5.7           \<4.6          \<4.8        \<4.3             5.7             5.6     5.6     \<4    \<4.4
                                       (8.3)                                                                                                                   

  **26**   NEU-1049   harmine          DYRK1B\              \<5.5         5.9            5.9          4.8               \<4.7           \<4.7   \<4.7   \<4    \<5.1
                                       (7.6)                                                                                                                   
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------

Confident in the structural diversity of these purchased compounds over the original PKIS hits, we assessed them using the same *T. brucei* assay that was performed in the HTS campaign. The results of these screening experiments are shown in [Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}; 13 compounds showed a growth inhibition pEC~50~ ≥ 6. This result represents an overall 50% hit rate (13/26) (compared to 4.2% for the overall HTS, which was performed on a random set of kinase-targeting inhibitors (1797 compounds with pEC~50~ ≥ 6, of 42444)). The *T. brucei* hit rate of the PKIS collection was 14.3% (53/369).

For example, [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"} shows the progression from GSK1173862A, an "active" ALK inhibitor in the PKIS, to four purchased ALK inhibitors. We note that two of the purchased inhibitors of human ALK (crizotinib and NVP-TAE684) are potent *T. brucei* proliferation inhibitors, despite their structural uniqueness compared to the original PKIS hit chemotype.

![Progression of a representative inhibitor class from a preferred human kinase to other ALK chemotypes with *T. brucei* proliferation activity.](id-2015-00136b_0004){#fig3}

We wished to test the significance of the observed enrichments using a wider set of investigational inhibitors of "preferred" kinases. We performed a retrospective analysis of HTS hit compounds that had previously emerged from internal GSK kinase inhibitor discovery programs. The expectation would be that if we were to select compounds from the HTS that were originally designed for one of the "preferred" human kinases, we should see an enhancement of hit rate against *T. brucei* when compared to inhibitors that were originally designed for other human kinases. The GSK database was searched to find screening hits active against the preferred kinases. After the removal of any PKIS compounds and their analogues included in this data set, nine human kinase screens were selected where at least 100 molecules were shared with the *T. brucei* screen. Contingency tables were built by comparing "actives/inactives" of *T. brucei* versus "actives/inactives" of the tested kinase, where "actives" are defined as having ≥80% inhibition in single-concentration assays. Chi-squared contingency table tests were performed and the corresponding *p* values determined as described above. Of these kinases analyzed in this way (ALK, ARK5, CDK2/cyclinA, GSK3β, DYRK1A, IGF1R, LCK, LRRK2, and PLK1), all showed conclusive evidence of significance in the chi-square test (*p* \< 0.01 and enrichments \> 1; [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}).

In addition, we checked that "non-preferred" kinases from our analysis did not show statistical association with *T. brucei* inhibition by using non-PKIS compounds in retrospective GSK screens (Figure S4 in the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.5b00136/suppl_file/id5b00136_si_001.pdf)).

These results, obtained with compounds structurally different from the PKIS and from the commercial set of inhibitors, further demonstrate that these particular human kinases are "preferred" in terms of their susceptibility to inhibitors that also show a high probability of anti-*T. brucei* activity.

Finally, we were interested to know whether these "preferred" *T. brucei* proliferation inhibitors would have a similar activity against other protozoan parasites. We reasoned that this would be possible because the three related kinetoplastid parasites, *T. brucei*, *T. cruzi*, and *Leishmania major*, have highly similar kinomes.^[@ref15]^ Thus, in the interest of trying to ascertain cross-parasite relevance of these "preferred" kinase inhibitors, we also assessed these compounds against *T. cruzi* intracellular amastigotes (Tulahuen strain), as well as against *L. major* promastigotes and intracellular amastigotes. In addition, we tested these inhibitors against the malaria-causing protozoan *Plasmodium falciparum* (D6 strain). Little activity was observed, indicating that these inhibitors are apparently "preferred" only as *T. brucei* growth inhibitors (see [Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"} and Figure S2 in the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.5b00136/suppl_file/id5b00136_si_001.pdf)).

![Fold enrichment of hit rate in *T. brucei* for actives in different preferred kinases utilizing the 80% human kinase inhibition cutoff. Data from single-concentration assays were retrieved (at least 100 compounds shared between *T. brucei* screen and kinase screen).](id-2015-00136b_0005){#fig4}

In summary, by testing the PKIS against *T. brucei* cells, we were able to identify kinases having inhibitors that are predisposed to be active against *T. brucei* cells. By performing a prospective analysis using structurally unique, commercially available inhibitors of these preferred kinases, and a retrospective analysis of historical GSK kinase HTS data, we confirmed that, in fact, inhibitors of these kinases are excellent starting points for launching new *T. brucei* drug discovery efforts. In contrast to using a human/parasite target homology-based approach for compound selection (also known as *target repurposing*), the utilization of such a "preferred" kinase analysis represents a method for a ligand-centric hit identification process that we term "*preferred lead repurposing*". Although we have presented evidence of such an approach working for hit identification for *T. brucei* drug discovery, the hits identified are not necessarily promising hits for other protozoan parasites. In due course, as PKIS screening results are reported for other pathogens such as *T. cruzi*, *L. major*, or *P. falciparum*, we look forward to identification of "preferred kinases" that can help focus lead repurposing efforts for these pathogens, as well. Finally, we note that several of the potent and nontoxic *T. brucei* proliferation inhibitors that we have identified in this work are compounds that have advanced into human clinical trials for a variety of indications. Encouraged by this, we have launched a program to further evaluate some of these compounds for direct repurposing against HAT and have initiated systematic medicinal chemistry programs for others to optimize potency and properties to be consistent with the targeted profile for new HAT therapeutics.

We note that some compounds may not be well suited for antiparasitic agents by virtue of their potent activity against human kinases. However, given that some of these kinase inhibitors are tolerated in humans for extended dosing regimens and that antiparasitic therapies would likely require a much shorter treatment period, we posit that in some cases exquisite selectivity for *T. brucei* cells versus over host kinases may not be required. On the other hand, it would seem prudent to minimize such host kinase activities, which would be the goal of further medicinal chemistry optimization. We propose that focusing on inhibitors of "preferred" human kinases provides a strong starting point for such optimization programs.

Methods {#sec2}
=======

Biological Assays {#sec2.1}
-----------------

The *T. brucei* and HepG2 cell assays were performed as previously described,^[@ref10]^ as were the *P. falciparum*, *L. major*, and *T. cruzi* assays.^[@ref8]^ The HepG2 cells were sourced ethically, and their research use was in accord with the terms of the informed consent.

Statistical Analyses {#sec2.2}
--------------------

A 2×2 contingency table was constructed, crossing *T. brucei* "active/inactive" with human kinase "active/inactive" (see [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.5b00136/suppl_file/id5b00136_si_001.pdf), Figure S1). A total number of 2016 contingency tables were generated (224 kinases × 3 kinase % inhibition cutoffs × 3 pEC~50~ cutoffs), which considered 81760 *T. brucei* activit---human kinase activity combinations (365 × 224).

From these tables, two conditional probabilities have been calculated as reported below:Finally, fold enrichment has been calculated as ratio of the two conditional probabilities:

If the number of compounds falling in quadrant A (Tb^+^\|Kinase^+^), that is, active against the selected kinase and active against *T. brucei*, is higher than the number of compounds falling in quadrant C (Tb^--^\|Kinase^+^), that is, active against the selected kinase but inactive against *T. brucei*, the fold enrichment will approach values higher than 1, whereas in the opposite cases the fold enrichment for that particular human kinase will be lower than 1. We elected to utilize the *T. brucei* pEC~50~ ≥ 6 cutoff, which provided a large enough sample to provide a statistically valid analysis, thus reducing the number of contingency tables to 672 (224 kinases × 3 kinase % inh cutoffs × 1 pEC~50~ cutoff). *p* values (chi-squared test) were calculated using R version 2.15.2 (2012-10-26).

Inhibitor Procurement {#sec2.3}
---------------------

Compounds were manually selected from Selleck Chemicals on the basis of their activity against "preferred" kinases ([Table S3](http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.5b00136/suppl_file/id5b00136_si_001.pdf)); compounds were used as received.

Similarity Calculations {#sec2.4}
-----------------------

To get an idea of the structural similarity of the commercial inhibitors tested and the PKIS compounds, the Tanimoto coefficient was calculated for each inhibitor and each PKIS compound by using the RDKit cheminformatic toolkit^[@ref19]^ and encoding the structures by means of topological fingerprints. The results were represented as box plots using the R program.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsinfecdis.5b00136](http://pubs.acs.org/doi/abs/10.1021/acsinfecdis.5b00136).Additional figures and data tables are compiled, including the full HTS results of the PKIS compounds tested against *T. brucei* cells, and all of the screening data of the purchased compounds against all of the parasites tested ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.5b00136/suppl_file/id5b00136_si_001.pdf))
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NTD
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HTS

:   high-throughput screening
